• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The crystalline D-sesquisodium salt of the oxa-β-lactam antibiotic diacid compound of the formula and process for its preparation via acetone dilution ot an aqueous solution of non-crystalline D,L-diacid and D,L-disodium salt.
    公开号:SU925251A3
    申请号:SU802912148
    申请日:1980-04-23
    公开日:1982-04-30
    发明作者:Джо Вилер Вильям
    申请人:Эли Лилли Энд Компани (Инофирма)；
    IPC主号:
    专利说明:

    KN
    (
    n
    (AND)
    or its disolium potassium, sodium or amines, such as triethylamine or procaine, which consists in acylation of Y-amino-Wo / methoxy-3- (1-methyltetrazol-5 Il) thiomethyl-1-oxadethia-3 cephem-4-carboxylic acid or its derivative derived ot- (p-hydroxyphenyl) malonic acid with the selection of the target product in the form of free diacid or its disoli 1.
    Diacid salts are antibiotic forms suitable for the parenteral administration of the antibiotic.
    as with most ft-lactam antibiotics, such as penicillins and cephalosporins. Although the pharmaceutically acceptable salts of oxa-lactamic acid are known, they are not obtained in the form of crystals with sufficient stability. For example, the disodium salt of 7E G-carbox-t .- (n-oxyphenyl) acetamido-7-methoxy-3- (t-methyltetrazol-5-yl) thiomethyl-1-oxadethia-3-cephem-A-carboxylic
    acid disodium oxa- / 5-lactamic acid of formula
    about
    I
    with I I 1 - .. and
    No oM tej-sJi
     -oN-:
    Co Oh to
    en
    (F)
    about
    get in amorphous form.
    The purpose of the invention is to increase the stabilities of salts of oxa-lactam acids.
    This goal is achieved by the present method of obtaining a new crystalline form of the O-configuration of the one-and-a-half sodium salt of 7-M-carboxy- "1- (p-hydroxyphenyl) acetamido-7o-methoxy-3 (1-methyltetrazol-5 yl) tyrmethyl-1-oxadethia -3 cephem-carboxylic acid, sodium d-salt of ox-a-lactamic acid diacid) of formula I, which consists in the following: In an aqueous solution of a mixture of a compound of formula II and a compound of formula III in a molar ratio of a compound of formula II to a compound of formula ItI from 1 : 1 to 1: 6, preferably from 1: 1 to 1: 2, respectively, are added it, and the solution was cooled to a temperature of from -35 to -YUS.
    The half-sodium di-acid O-salt of formula I is obtained as crystalline needles, melting in the range from 175 to disintegrating. The ultraviolet absorption spectrum of the solution of this salt in methyl alcohol has absorption maxima at 228 nm (17300) and at 270 nm (f, 11800).
    The ratio of D-epimer to L-epimer in the one-and-a-half sodium salt prepared by the proposed method is determined by high performance liquid chromatography (HPLC), and this ratio varies from 93 to E8 Depimer.
    The salt form obtained by the proposed method as a sodium sesame salt is characterized using atomic absorption analysis of products, elemental analysis and titration. The calculated percentage of sodium in one-half sodium salt is 5.5b. The percentage of sodium obtained by atomic absorption analysis based on the water content (Karl Fischer water determination) and the presence of some acetone in the product is within the experimental error, although it varies from crystallization to crystallization. Sodium sodium d-salt in water has an initial pH, and as a result of titration of its solution in water, the following three pKa values are observed: pKa 2, S; pKa2 3 "7; pKa 10.2. The one-and-a-half sodium salt of formula I forms a pharmaceutically convenient crystalline form that can be used to prepare parenterally prescribed formulations. According to the method of the invention, a mixture of 0,1-diacid of formula I and a 0,1-diyrium salt of formula III is dissolved in water at 15-35 ° C and the solution is diluted with acetone until the cloud point is reached, then the solution is cooled to crystallization temperature from - 35 until the crystallization of the O-epimeric sodium sesquito salt, the crystalline sodium sesame salt is separated from the cold solution, washed with an appropriate solvent, such as acetone or diethyl ether, and dried. The crystallization of the O-epimeric sodium sesquito salt is induced by adding as a seed the O-epimer sodium sesame salt in a cold aqueous solution at the cloud point. In this process, the filtrate remaining after the isolation of the sodium half-salt 0-salt can be reused to obtain an additional amount of D-zimer. To obtain additional sodium sesquihydrate, the filtrate is diluted with acetone until it reaches a cloud point and cooled to the crystallization temperature. The 0.1-diacid and its 0.1-disodium salt can be mixed together in different proportions in the solid state until dissolved in water, or dissolved separately in water and mixed as solutions. In addition, a solution of the diacid and the disodium salt for use in this method can be obtained by adding from 1 to 1.5 equivalents of sodium hydroxide to a suspension of amorphous O, diacid in water. 0,1-diacid is partially soluble in water. Thereafter, the final solution is diluted with acetone and cooled to the crystallization temperature. Although the concentration of the aqueous solution of D, L-diacid and the 0.1-disodium salt is not a decisive parameter, however, the highest yields of the sodium d-sodium d-salt are observed when the concentration of the solution is from 0.1 to 1 g of the total weight of 0.1-diacid and 0, and disodium salt per 1 ml of water. As indicated above, 0, and -diacid and 0,1-disodium salt can be in solution in different ratios to each other. {The ratio of D, U-disodium salt to 0,1-diacid in solution can be from 1: 1 to 6: 1. At higher ratios of disolyl to diacid, the 0.1-disodium salt may co-precipitate with the target sesquimate 0-salt. The preferred ratio is from 1 to 2 mol of the 0.1-disodium salt per 1 mol of D, L acid. When diluted with an aqueous solution. 0, disodium salt and D, L-diacid acetone cloud point is achieved when the content in the diluted solution is from 80 to 90 by volume of acetone. Obtained by the proposed method, the crystals of sodium sesquiar D-salt are salvated with acetone. Acetone is contained as a solvate in an amount of about 1: 1 ho relative to the half-salt. Acetone is weakly bound to one-half salt crystals and most of it can be removed by evaporation under vacuum. Acetone serves as a precipitant, and also participates in the formation of a crystalline solvate, and thus contributes to the formation of a crystalline sodium sesame salt. The purity of one-and-a-half sodium D-salt can be enhanced by recrystallization. For example, one-and-a-half sodium O-salt is dissolved in water and the solution is diluted with acetone to a cloud point. Under curing at the crystallization temperature, one-and-a-half sodium D-salt precipitates again in the form of crystalline needles solvated by acetone. In accordance with the proposed method, a crystalline sodium sesquint D-salt is obtained, which is practically free of L-epimer. The term “substantially free of L-zpimera” as used herein means that the crystalline one-and-a-half salt of a 90 or more D-epimeric form. As noted above, the ratio of D-epimer and L-epimer in the crystalline sodium sesquito salt is determined by high performance liquid chromatography (HPLC). The following HPLC system was used: Waters Associates Bondpak C-l8 column; flow rate 3 ml / min; solvent: 100 hours. 0.1 and. ammonium acetate, 6 parts of methyl alcohol; Growth sample phosphate buffer, pH U ,; sample concentration 1 mg / m sample volume 15 µl. Example. A mixture of 0.5 g of hydroxy-lactam 0,1-diacid and 0.5 g of an amorphous 0.1-disodium salt is dissolved in 1.5 ml of water and acetone is added at a room temperature to form a weak turbidity. The solution is cooled, seeded with sodium D-c crystals and kept at a temperature of about -20 ° C for a few hours. The crystalline sodium sesquio O-salt precipitated from the cold solution is collected by filtration, washed with acetone and dried under vacuum. Dry crystal needles weighs 0.207 g. (Ristals melt with destruction at 175-180 ° C. Analysis by high pressure liquid chromatography shows that the crystalline product contains 93% O-epimer and 7% L-epimer. P p and measure 2. A solution of 2.5 g of the 0.1-hydroxy-f-lactam disodium salt and 2.5 g of the 0.1-hydroxy-lactam diacid in 5 ml of water is diluted with an ac tone at room temperature until reaching the point A slightly turbid solution is cooled to crystallization. D-hydroxy-J8-lactam crystalline sodium sesame salt is collected by filtering This is washed with diethyl ether and dried. Dry crystals weigh 2.77 The filtrate is diluted with acetone to a cloud point and held at. The secondary yield of the resulting sodium O-salt is 0, the crystalline product contains 7.5 water (Karl Fischer ) and 96.7% O-epimera (HPLC). EXAMPLE 3: PafTBOp 0.6 g D, L-hydroxy-lactam dinate 5th salt and 0.3 g D, L-diacid (ratio 2 : 1) in 0.9 ml of water, diluted with opacifying point acetone and allowed to crystallize at a temperature of approximately -20 ° C. The crystals of sodium bicarbonate O-salt are filtered, washed and dried. The crystalline product weighs 0.55 g. Example. Recrystallization of D-hydroxy-lactam sodium sesame. A solution of 2.068 g of sodium d-salt and half soda in 2 ml of water is diluted with acetone to a cloud point and, after seed, held at a temperature of approximately -20 ° C. The primary yield of sesquicum sodium O-salt is collected by filtration, washed and dried. The colorless crystalline product weighs 9bO mg. The following analytical data were obtained for recrystallized one-and-a-half sodium O-salt. Calculated: C 2.03, H 3, N and, 71. C2oH | 8.5NeOq Ma ,, 5-1NgO Found,%: C 2.00; H 3.19; N 1i, 52. Sodium atomic absorption analysis. Calculated: Na 5.56 (including 7,% water and 5% acetone). Found: Na 5.9. The ratio of D / L (HPLC),%: 95,7; tJ. Titration (N20): initially pH 3.8; pKa, 2.5; pKag 3.7; pKa 10.2. When titrating, to complete the titration of the sodium sesquichite sample from pH 3.7 to pH 5.7, 0.5 equivalent of sodium hydroxide is required. Apparent molecular weight (titration) 5bЗ; residual solvents (NMR): acetone 5.15%; water content (Karl Fischer) 7.36%; Specific rotation: -l8.05 (pH 7.0, buffer); -T11.53 (pH 7.0, buffer). Example5. To a solution of 1 g (1.92 mmol) of amorphous 0 and diacid in O, 8 ml of water, 2.28 ml of sodium hydroxide (2.28 mmol) are added. After addition of the base, the solution is diluted with acetone to a cloud point and cooled at approximately. The cold solution is seeded with crystals of sodium sesame D-salt and kept cold. Sesquiouse O-salt, shake out
    权利要求:
    Claims (2)
    [1]
    Claim
    1. A method of obtaining a crystalline form of the D-configuration one and a half
    925251 10 sodium salt 7β ~ [^ -carboxy-d- (p-hydroxyphenyl) acetamido] -7 * -methoxy-3 * - (1-methyltetrazol-5 “yl) -thiomethyl-1-oxadetia-3-cefem-4 -carboxylic acid of formula I characterized in that to an aqueous solution of a mixture of D, L-form 7D- [σί-carboxy-L- (p-hydroxyphenyl) acetone mido] -7c £ “methoxy-3- (1-methyltetrazole ~ 5 _ il) -thiomethyl-1-oxadetia-3-cephem -4-carboxylic acid of the formula II and Ο, ί-form of disodium salt, 7β-carboxy-d - (p-hydroxyphenyl) acetamido _ / - 7в <-methoxy-3- ( 1-methyl tetrazol-5'-yl) -thiomethyl-1-oxadetia- 3-cephem-4-carboxylic acid of the formula I 11 in a molar ratio of compound f rmuly II to a compound of formula III of 1: 1 to 1: 6, respectively, were added acetone and the solution was cooled to -35 to -10 ° C.
    [2]
    2. The method of pop. 1, characterized in that the process is carried out at a molar ratio of the compounds of formula I I to the compounds of formula I I I from 1: 1 to 1: 2, respectively.
    类似技术:
    公开号 | 公开日 | 专利标题
    RU2081121C1|1997-06-10|Method of synthesis of clavulanic acid or its pharmaceutically acceptable salts and ethers, clavulanic acid salt with amine
    AU615509B2|1991-10-03|Temperature stable crystalline salts of 7-|-alpha-|-methoxyiminoacetamidol)-3- |methyl)-3-cephem-4-carboxylate
    SU925251A3|1982-04-30|Process for producing d-configuration crystalline form of sesquisalt of sodium 7beta-[alpha-carboxy-alpha-| acetamido-7-alpha-methoxy-3-| thiomethyl-2-oxadethia-3-cefem-4-carboxyate
    IE862078L|1987-02-05|Cephalosporin salts
    SU458131A3|1975-01-25|The method of obtaining cipher bases of 7-amino-3-desatzfetoxycephalosporanic acid
    US4727070A|1988-02-23|3-Propenzl cephalosporin isomer separation process and derivative
    SU1630613A3|1991-02-23|Process for preparation of crystalline half-hydrade of cefadroxyl
    JPH08506332A|1996-07-09|Process for producing tetrazole-5-carboxylic acid derivative
    SU558644A3|1977-05-15|The method of obtaining imidazoles or their salts
    US4754030A|1988-06-28|Cefbuperazone crystalline triethylamine salt
    US4168376A|1979-09-18|Process for crystalline sodium cefamandole
    CA1079736A|1980-06-17|Crystalline calcium di-clavulanate dihydrate
    SU860705A3|1981-08-30|Method of preparing crystalline form of d-configuration of diammonium salt of 7-beta-/-alpha-carboxy-alpha-p-oxyphenyl acetamido /-7-alpha-methoxy-3-|-thiomethyl-1-oxydethia-3-cephem-4-carboxalic acid
    DK167319B1|1993-10-11|STABLE HYDRATE OF A PENICILLIN DERIVATIVE AND PROCEDURE FOR PREPARING THEREOF
    US3947414A|1976-03-30|Cefamandole derivatives
    CA1282407C|1991-04-02|Crystalline cephem carboxylic acid addition salt
    US3983109A|1976-09-28|Process for recovering cephalosporin C from A fermentation broth as the N-| derivative
    US4680389A|1987-07-14|Temperature stable crystalline di| and di| adducts of cephalosporin derivatives
    US3947415A|1976-03-30|Cefamandole derivatives
    DE2731261A1|1978-01-19|3- | -CEPHALOSPORIN DERIVATIVES AND THEIR SALT, METHOD FOR THEIR MANUFACTURING AND MEDICINAL PRODUCTS
    US4124636A|1978-11-07|Method of preparing monopotassium L-malate and its monohydrate
    KR950013570B1|1995-11-09|The preparation method of cefodizime bisodium salts
    DE1445685C|1971-10-07|7- | -cephaIosporanic acid
    RU2135502C1|1999-08-27|Clavulanic acid diamine salts, method of their synthesis |, method of synthesis of clavulanic acid or its pharmaceutically acceptable salt, method of purification of clavulanic acid of its salt
    RU2137775C1|1999-09-20|Method of isolating oxacilline sodium salt
    同族专利:
    公开号 | 公开日
    NZ193482A|1982-03-23|
    PT71115A|1980-05-01|
    IL59895A|1983-05-15|
    DE3067412D1|1984-05-17|
    DK172880A|1980-10-25|
    IT1141294B|1986-10-01|
    JPS6242915B2|1987-09-10|
    DD150205A5|1981-08-19|
    AT368158B|1982-09-27|
    IE49703B1|1985-11-27|
    AU531272B2|1983-08-18|
    YU108180A|1983-02-28|
    CA1124236A|1982-05-25|
    US4259485A|1981-03-31|
    ATA207380A|1982-01-15|
    IE800804L|1980-10-24|
    ES8200110A1|1981-10-16|
    BE882849A|1980-10-20|
    KR840000036B1|1984-01-28|
    PL223649A1|1981-02-13|
    CS212347B2|1982-03-26|
    LU82384A1|1980-07-31|
    CH645901A5|1984-10-31|
    EG14334A|1983-12-31|
    GB2047703A|1980-12-03|
    PL124423B1|1983-01-31|
    FR2455043B1|1983-08-05|
    KR830002778A|1983-05-30|
    GR68048B|1981-10-29|
    IT8021527D0|1980-04-21|
    RO79315A|1982-08-17|
    FR2455043A1|1980-11-21|
    GB2047703B|1983-04-20|
    JPS55143992A|1980-11-10|
    AU5763380A|1980-10-30|
    ZA802329B|1981-11-25|
    AR225174A1|1982-02-26|
    EP0018760B1|1984-04-11|
    EP0018760A1|1980-11-12|
    FI801252A|1980-10-25|
    ES490828A0|1981-10-16|
    PH15146A|1982-08-24|
    HU182127B|1983-12-28|
    BG34904A3|1983-12-15|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    RU2555360C2|2012-11-06|2015-07-10|Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации|Method for measuring water in complex compounds|CA1085392A|1976-03-25|1980-09-09|Masayuki Narisada|Arylmalonamido-1-oxadethiacephalosporins|
    GB1557552A|1977-02-15|1979-12-12|Shionogi & Co|1 oxadethiacepham compounds|
    CA1100962A|1977-04-28|1981-05-12|Yoshio Hamashima|Haloarylmalonamidooxacephalosporins|
    JPS609718B2|1977-08-25|1985-03-12|Shionogi & Co|
    BE871213R|1978-10-12|1979-02-01|Shionogi & Co|ARYLMALONAMIDO-1-OXADETHIACEPHALOSPORINS|JPS56103185A|1980-01-22|1981-08-18|Shionogi & Co Ltd|Malonamidoxa-dethia-cephem compound|
    JPS6364405B2|1980-06-23|1988-12-12|
    JPH0149271B2|1982-07-02|1989-10-24|Shionogi & Co|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US06/032,840|US4259485A|1979-04-24|1979-04-24|Crystallization process|
    [返回顶部]